Strain and sex-related behavioral variability of oxycodone dependence in rats.
Opioid use disorder
Oxycodone
Rat
Self-administration
Sex
Strain
Journal
Neuropharmacology
ISSN: 1873-7064
Titre abrégé: Neuropharmacology
Pays: England
ID NLM: 0236217
Informations de publication
Date de publication:
01 10 2023
01 10 2023
Historique:
received:
04
04
2023
revised:
05
06
2023
accepted:
07
06
2023
medline:
14
7
2023
pubmed:
17
6
2023
entrez:
16
6
2023
Statut:
ppublish
Résumé
Over the past two decades, the escalating prescription of opioid medications for pain management has culminated in a widespread opioid epidemic, significantly impacting public health, social dynamics, and economic stability. The urgent need for improved treatments for opioid addiction necessitates a deeper understanding of its biological underpinnings, with genetic variations playing a crucial role in individual susceptibility to opioid use disorder (OUD) and influencing clinical practices. In this study, we leverage the genetic diversity of four rat strains (ACI/N, BN/NHsd, WKY/N, and F344/N) to examine the contribution of genetic factors to oxycodone metabolism and addiction-like behaviors. We used the extended access to intravenous oxycodone self-administration procedure (12 h/day, 0.15 mg/kg/injection) to comprehensively characterize oxycodone-related behaviors and pharmacokinetics. We measured escalation of oxycodone self-administration, motivation for drug consumption, tolerance to the analgesic effects of oxycodone, withdrawal-induced hyperalgesia, and oxycodone-induced respiratory depression. Additionally, we examined oxycodone-seeking behavior after four weeks of withdrawal by reintroducing the animals to environmental and cue stimuli previously associated with oxycodone self-administration. The findings revealed notable strain differences in several behavioral measures, including oxycodone metabolism. Intriguingly, BN/NHsd and WKY/N strains exhibited similar drug intake and escalation patterns but displayed significant disparities in oxycodone and oxymorphone metabolism. Minimal sex differences were observed within strains, primarily relating to oxycodone metabolism. In conclusion, this study identifies strain differences in the behavioral responses and pharmacokinetics associated with oxycodone self-administration in rats, providing a robust foundation for identifying genetic and molecular variants associated with various facets of the opioid addiction process.
Identifiants
pubmed: 37327971
pii: S0028-3908(23)00225-3
doi: 10.1016/j.neuropharm.2023.109635
pmc: PMC10353778
mid: NIHMS1914102
pii:
doi:
Substances chimiques
Oxycodone
CD35PMG570
Analgesics, Opioid
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
109635Subventions
Organisme : NIDA NIH HHS
ID : U01 DA051972
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA028549
Pays : United States
Organisme : NIDA NIH HHS
ID : U01 DA044451
Pays : United States
Organisme : NIAAA NIH HHS
ID : T32 AA007456
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA056602
Pays : United States
Organisme : NIAAA NIH HHS
ID : P60 AA006420
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA026999
Pays : United States
Organisme : NIAAA NIH HHS
ID : P50 AA006420
Pays : United States
Organisme : NIDA NIH HHS
ID : R21 DA053443
Pays : United States
Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest This work was supported by the National Institute on Drug Abuse [DA051972 and DA056602 to FT, CB and GdG, DA044451 to OG and DA053443 to RM-F], by the National Institute on Alcohol Abuse and Alcoholism [T32 AA007456 to MRD, AA026999, AA028549 and AA006420 to RM-F] by the Brain & Behavior Research Foundation [2020 NARSAD Young Investigator Award to GdG] and from the Preclinical Addiction Research Consortium (PARC) at the University of California San Diego. The authors declare no competing interests.
Références
Synapse. 1992 Nov;12(3):242-53
pubmed: 1362292
Eur J Pharmacol. 2015 Feb 5;748:76-82
pubmed: 25530266
Neuroscience. 2009 Sep 15;162(4):1255-64
pubmed: 19460419
Behav Brain Res. 2008 Dec 12;194(2):146-51
pubmed: 18656501
Psychopharmacology (Berl). 2017 Jan;234(2):223-234
pubmed: 27714428
Neuroscience. 2013 Jan 29;230:151-6
pubmed: 23153991
Neuropharmacology. 1996;35(8):1131-4
pubmed: 9121616
Pharmacol Biochem Behav. 2011 Mar;98(1):28-34
pubmed: 21147152
Behav Neurosci. 2007 Apr;121(2):380-8
pubmed: 17469928
Proc Natl Acad Sci U S A. 2012 Oct 30;109(44):18156-61
pubmed: 23071333
Psychopharmacology (Berl). 2021 Dec;238(12):3423-3433
pubmed: 34415376
Eur Neuropsychopharmacol. 2008 Aug;18(8):551-6
pubmed: 18284941
Neuropharmacology. 2009;56 Suppl 1:205-12
pubmed: 18718480
Life Sci. 1997;61(20):2057-64
pubmed: 9366513
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11042-6
pubmed: 11572966
Nat Genet. 2006 Aug;38(8):879-87
pubmed: 16832355
Front Behav Neurosci. 2022 Mar 03;16:832899
pubmed: 35316955
Psychopharmacology (Berl). 2021 Sep;238(9):2503-2514
pubmed: 34106317
J Pharmacol Exp Ther. 2017 Sep;362(3):378-384
pubmed: 28645915
Psychopharmacology (Berl). 1993;112(2-3):352-8
pubmed: 7871041
BMJ. 2013 May 03;346:f2690
pubmed: 23645858
J Neurosci. 2012 May 30;32(22):7563-71
pubmed: 22649234
Psychoneuroendocrinology. 2002 Jan-Feb;27(1-2):35-69
pubmed: 11750769
Psychopharmacology (Berl). 2012 Mar;220(1):163-72
pubmed: 21894484
Int J Neuropsychopharmacol. 2009 Sep;12(8):1033-44
pubmed: 19341511
Br J Pharmacol. 2014 Dec;171(23):5407-16
pubmed: 25048682
Eur J Pharmacol. 2000 Jan 17;387(3):R23-5
pubmed: 10650185
Neuropsychopharmacology. 2009 Mar;34(4):820-33
pubmed: 18800068
Alcohol Clin Exp Res. 2019 Oct;43(10):2079-2089
pubmed: 31403700
Proc Natl Acad Sci U S A. 1988 Jul;85(14):5274-8
pubmed: 2899326
Neuron. 2008 Jul 10;59(1):11-34
pubmed: 18614026
Psychopharmacology (Berl). 2020 May;237(5):1545-1555
pubmed: 32114633
Neuropsychopharmacology. 2010 Jan;35(1):217-38
pubmed: 19710631
Clin Exp Pharmacol Physiol. 2008 Mar;35(3):295-302
pubmed: 17973932
Neuropharmacology. 1993 Sep;32(9):885-93
pubmed: 8232791
Front Behav Neurosci. 2022 Nov 24;16:1035350
pubmed: 36505730
J Psychopharmacol. 2011 Jun;25(6):783-91
pubmed: 20488829
PLoS Biol. 2010 Jun 29;8(6):e1000412
pubmed: 20613859
Brain Res. 1999 Mar 13;821(2):350-5
pubmed: 10064821
Proc Natl Acad Sci U S A. 2020 Jan 28;117(4):2140-2148
pubmed: 31932450
Neuropsychopharmacology. 2009 Apr;34(5):1209-22
pubmed: 18563059
Psychopharmacology (Berl). 1987;92(3):327-33
pubmed: 3114785
J Neurosci. 2013 Dec 4;33(49):19384-92
pubmed: 24305833
J Neurosci. 2000 Sep 15;20(18):6983-8
pubmed: 10995843
Neuropsychopharmacology. 2008 Sep;33(10):2474-82
pubmed: 18033234
Arch Gen Psychiatry. 1990 Apr;47(4):325-30
pubmed: 2157379
Lab Anim. 2007 Jul;41(3):337-44
pubmed: 17640461
Front Behav Neurosci. 2020 Jan 14;13:292
pubmed: 31992976
Psychopharmacology (Berl). 2017 Mar;234(6):977-987
pubmed: 28127624
Neuropharmacology. 2009 Jul;57(1):8-17
pubmed: 19376142
Psychopharmacology (Berl). 2006 Jun;186(2):177-84
pubmed: 16572262
Am J Psychiatry. 2005 Aug;162(8):1403-13
pubmed: 16055761
Nat Genet. 2013 Jul;45(7):767-75
pubmed: 23708188
eNeuro. 2021 Jun 17;8(3):
pubmed: 33875455